Traws Pharma Reports Officer/Director Changes & Compensatory Info
Ticker: TRAW · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $500, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
TL;DR
Traws Pharma (fka Onconova) filed an 8-K detailing exec/director changes and comp. Watch for strategic shifts.
AI Summary
Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on October 6, 2025, reporting events as of October 1, 2025. The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
Changes in key personnel and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if numerous or unexpected, can indicate internal instability or strategic realignments that carry inherent risks.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Onconova Therapeutics, Inc. (company) — Former Company Name
- October 1, 2025 (date) — Earliest event reported date
- October 6, 2025 (date) — Filing date
FAQ
What specific officer or director positions were affected by the changes reported in the 8-K?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', but the specific names and roles are not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 1, 2025.
What is the SIC code for Traws Pharma, Inc.?
The Standard Industrial Classification (SIC) code for Traws Pharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the SEC file number for Traws Pharma, Inc.?
The SEC file number for Traws Pharma, Inc. is 001-36020.
Has Traws Pharma, Inc. undergone any previous name changes?
Yes, Traws Pharma, Inc. was formerly known as Onconova Therapeutics, Inc., with name changes recorded on May 26, 2009, and December 26, 2000.
Filing Stats: 923 words · 4 min read · ~3 pages · Grade level 10.2 · Accepted 2025-10-06 07:00:39
Key Financial Figures
- $500 — ng services. The Company will pay Stout $500 per hour, up to a maximum of $50,000 pe
- $50,000 — Stout $500 per hour, up to a maximum of $50,000 per month, for services provided by Mr.
Filing Documents
- tm2528048d1_8k.htm (8-K) — 29KB
- tm2528048d1_ex99-1.htm (EX-99.1) — 19KB
- 0001104659-25-096920.txt ( ) — 216KB
- tmb-20251001.xsd (EX-101.SCH) — 3KB
- tmb-20251001_lab.xml (EX-101.LAB) — 33KB
- tmb-20251001_pre.xml (EX-101.PRE) — 22KB
- tm2528048d1_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 6, 2025, the Company issued a press release (the "Press Release") announcing the appointment of Dr. Leaman to the Board and the change in Dr. Dukes' and Mr. Parker's titles. A copy of the Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated by reference into this Item 7.01. The information set forth under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 6, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 6, 2025 TRAWS PHARMA, INC. By: /s/ Iain Dukes Iain Dukes Chief Executive Officer